Search Results - "Lee, Daniel Junseung"

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results by Sallman, David Andrew, Al Malki, Monzr, Asch, Adam Steven, Lee, Daniel Junseung, Kambhampati, Suman, Donnellan, William Bruce, Bradley, Terrence James, Vyas, Paresh, Jeyakumar, Deepa, Marcucci, Guido, Komrokji, Rami S., Van Elk, Joanna, Lin, Ming, Maute, Roy, Volkmer, Jens-Peter, Takimoto, Chris H.M., Chao, Mark, Daver, Naval Guastad

“…Abstract only 7507 Background: Magrolimab (Hu5F9-G4) is an antibody blocking CD47, a macrophage immune checkpoint and don’t eat me signal on cancers. It…”
Get full text

The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results by Sallman, David Andrew, Donnellan, William Bruce, Asch, Adam Steven, Lee, Daniel Junseung, Al Malki, Monzr, Marcucci, Guido, Pollyea, Daniel Aaron, Kambhampati, Suman, Komrokji, Rami S., Van Elk, Joanna, Lin, Ming, Agoram, Balaji, Chen, James Y, Volkmer, Jens-Peter, Takimoto, Chris H.M., Chao, Mark, Vyas, Paresh

“…Abstract only 7009 Background: Hu5F9-G4 (5F9) is an antibody targeting CD47, a macrophage immune checkpoint and “don’t eat me” signal on cancers. CD47 blockade…”
Get full text